• Something wrong with this record ?

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model

S. Shen, C. Picci, K. Ustinova, V. Benoy, Z. Kutil, G. Zhang, MT. Tavares, J. Pavlíček, CA. Zimprich, MB. Robers, L. Van Den Bosch, C. Bařinka, B. Langley, AP. Kozikowski

. 2021 ; 64 (8) : 4810-4840. [pub] 20210408

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21018794

Grant support
R01 NS079183 NINDS NIH HHS - United States
R43 HD093464 NICHD NIH HHS - United States
R41 AG058283 NIA NIH HHS - United States

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and selective HDAC6i that was shown to be effective in mouse models of Fragile X syndrome and Charcot-Marie-Tooth disease type 2A (CMT2A). In this study, we report the discovery of a new THQ-capped HDAC6i, termed SW-101 (1s), that possesses excellent HDAC6 potency and selectivity, together with markedly improved metabolic stability and druglike properties compared to SW-100 (1a). X-ray crystallography data reveal the molecular basis of HDAC6 inhibition by SW-101 (1s). Importantly, we demonstrate that SW-101 (1s) treatment elevates the impaired level of acetylated α-tubulin in the distal sciatic nerve, counteracts progressive motor dysfunction, and ameliorates neuropathic symptoms in a CMT2A mouse model bearing mutant MFN2. Taken together, these results bode well for the further development of SW-101 (1s) as a disease-modifying HDAC6i.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018794
003      
CZ-PrNML
005      
20210830100348.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.0c02210 $2 doi
035    __
$a (PubMed)33830764
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Shen, Sida $u Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States
245    10
$a Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model / $c S. Shen, C. Picci, K. Ustinova, V. Benoy, Z. Kutil, G. Zhang, MT. Tavares, J. Pavlíček, CA. Zimprich, MB. Robers, L. Van Den Bosch, C. Bařinka, B. Langley, AP. Kozikowski
520    9_
$a Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and selective HDAC6i that was shown to be effective in mouse models of Fragile X syndrome and Charcot-Marie-Tooth disease type 2A (CMT2A). In this study, we report the discovery of a new THQ-capped HDAC6i, termed SW-101 (1s), that possesses excellent HDAC6 potency and selectivity, together with markedly improved metabolic stability and druglike properties compared to SW-100 (1a). X-ray crystallography data reveal the molecular basis of HDAC6 inhibition by SW-101 (1s). Importantly, we demonstrate that SW-101 (1s) treatment elevates the impaired level of acetylated α-tubulin in the distal sciatic nerve, counteracts progressive motor dysfunction, and ameliorates neuropathic symptoms in a CMT2A mouse model bearing mutant MFN2. Taken together, these results bode well for the further development of SW-101 (1s) as a disease-modifying HDAC6i.
650    _2
$a acetylace $7 D000107
650    _2
$a zvířata $7 D000818
650    _2
$a benzamidy $x chemie $x metabolismus $7 D001549
650    _2
$a vazebná místa $7 D001665
650    _2
$a Charcotova-Marieova-Toothova nemoc $x farmakoterapie $x metabolismus $x patologie $7 D002607
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a poločas $7 D006207
650    _2
$a histondeacetylasa 6 $x antagonisté a inhibitory $x metabolismus $7 D000073864
650    _2
$a inhibitory histondeacetylas $x chemie $x metabolismus $x terapeutické užití $7 D056572
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a fenotyp $7 D010641
650    _2
$a protein - isoformy $x antagonisté a inhibitory $x metabolismus $7 D020033
650    _2
$a chinoliny $x chemie $x metabolismus $x terapeutické užití $7 D011804
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a tubulin $x metabolismus $7 D014404
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Picci, Cristina $u School of Health, The University of Waikato, Private Bag 3105, Hamilton 3240, New Zealand
700    1_
$a Ustinova, Kseniya $u Institute of Biotechnology of the Czech Academy of Sciences, 252 50 Vestec, Czech Republic
700    1_
$a Benoy, Veronick $u Laboratory of Neurobiology, Center for Brain & Disease (VIB) and Leuven Brain Institute (LBI), KU Leuven, B-3000 Leuven, Belgium
700    1_
$a Kutil, Zsófia $u Institute of Biotechnology of the Czech Academy of Sciences, 252 50 Vestec, Czech Republic
700    1_
$a Zhang, Guiping $u Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States
700    1_
$a Tavares, Maurício T $u Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States
700    1_
$a Pavlíček, Jiří $u Institute of Biotechnology of the Czech Academy of Sciences, 252 50 Vestec, Czech Republic
700    1_
$a Zimprich, Chad A $u Promega Corporation, Madison, Wisconsin 53711, United States
700    1_
$a Robers, Matthew B $u Promega Corporation, Madison, Wisconsin 53711, United States
700    1_
$a Van Den Bosch, Ludo $u Laboratory of Neurobiology, Center for Brain & Disease (VIB) and Leuven Brain Institute (LBI), KU Leuven, B-3000 Leuven, Belgium
700    1_
$a Bařinka, Cyril $u Institute of Biotechnology of the Czech Academy of Sciences, 252 50 Vestec, Czech Republic
700    1_
$a Langley, Brett $u School of Health, The University of Waikato, Private Bag 3105, Hamilton 3240, New Zealand
700    1_
$a Kozikowski, Alan P $u Bright Minds Biosciences, Toronto, ON M5H 3V9, Canada
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 64, č. 8 (2021), s. 4810-4840
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33830764 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100348 $b ABA008
999    __
$a ok $b bmc $g 1689779 $s 1139240
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 64 $c 8 $d 4810-4840 $e 20210408 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
GRA    __
$a R01 NS079183 $p NINDS NIH HHS $2 United States
GRA    __
$a R43 HD093464 $p NICHD NIH HHS $2 United States
GRA    __
$a R41 AG058283 $p NIA NIH HHS $2 United States
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options